Concord Drugs Ltd vs Gland Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 82.65 as of 06 May 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Gland Pharma Ltd changed from 44.3 on March 2022 to 40.7 on March 2021 . This represents a CAGR of -1.68% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Gland Pharma Ltd changed from ₹ 53713 crore on March 2022 to ₹ 40535 crore on March 2021 . This represents a CAGR of -5.47% over 5 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Gland Pharma Ltd for the Dec '25 is ₹ 1758 crore as compare to the Sep '25 revenue of ₹ 1571 crore. This represent the growth of 11.93% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Gland Pharma Ltd for the Dec '25 is ₹ 473.7 crore as compare to the Sep '25 ebitda of ₹ 398.05 crore. This represent the growth of 19.01% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Gland Pharma Ltd changed from ₹ 143.76 crore to ₹ 261.48 crore over 7 quarters. This represents a CAGR of 40.75% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gland Pharma Ltd changed from 31.57 % on March 2024 to 27.22 % on March 2025 . This represents a CAGR of -7.14% over 2 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Gland Pharma Ltd

Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad.
Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
The Company is primarily engaged in manufacturing injectable formulations. Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, with operations extending to over 60 countries including the United States, Europe, Canada, Australia, and India.
Primarily functioning under a B2B model, the company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems.

FAQs for the comparison of Concord Drugs Ltd and Gland Pharma Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Gland Pharma Ltd?

Market cap of Concord Drugs Ltd is 112 Cr while Market cap of Gland Pharma Ltd is 29,212 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Gland Pharma Ltd?

The stock performance of Concord Drugs Ltd and Gland Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Gland Pharma Ltd?

As of May 6, 2026, the Concord Drugs Ltd stock price is INR ₹85.04. On the other hand, Gland Pharma Ltd stock price is INR ₹1773.1.

How do dividend payouts of Concord Drugs Ltd and Gland Pharma Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Gland Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.